

At a Glance Hereditary Tyrosinemia Type 1 (HT-1)

Deficient enzyme: Fumarylacetoacetate Hydrolase (FAH)

Toxic Metabolite: Succinylacetone and succinylacetoacetate

Clinical presentation, if untreated: failure to thrive, rickets, hepatic failure, renal failure, neurologic

comorbidities

Restricted Amino Acids: Phenylalanine and Tyrosine

Goal Treatment Range¹:

Plasma Phenylalanine: 20-80 μmol/L Plasma Tyrosine: 200-600 μmol/L

Nutrient Needs by Age²

Age	Phenylalanine plus Tyrosine mg/kg/d	Total Protein g/kg/d	Energy kcal/kg/d
0-3 mo	65 - 155	3.0 - 3.5	120 (95 - 145)
3-6 mo	55 - 135	3.0 - 3.5	120 (95 - 145)
6-9 mo	50 - 120	2.5 - 3.0	110 (80 - 135)
9-12 mo	40 - 105	2.5 - 3.0	105 (80-135)
1-4 yrs	380 – 800 mg/d	>/= 30 g/d	1300 (900-1800)

Starting a HT-1 Diet

- 1. Determine goals for Phenylalanine (mg) plus Tyrosine (mg), Total Protein (g), and Energy (kcal) -use 50 mg Phe = 1 g protein to calculate milligrams of phe from protein
- 2. Calculate amount of whole protein source (breast milk, infant formula, food) needed to meet phe + tyr goal.
- 3. Calculate amount of medical food needed in addition to the whole protein source to meet total protein goal.
- 4. Calculate energy intake from whole protein and medical food sources to ensure total calorie needs are met.

Hereditary Tyrosinemia Type 1 (HT-1)

Medical Food Therapy

	Abbott abbottnutrition.com	Cambrooke Cambrooke.com	Mead Johnson hcp.meadjonson.com	Nutricia NutriciaMetabolics.com	Vitaflo www.vitafloUSA.com
Infant (0-1 yr)	Tyrex [®] -1		Tyros 1	TYR Anamix [®] Early Years	
Toddler & Young Children	Tyrex-1 Tyrex-2	*Tylactin® Complete Tylactin RTD 15 Tylactin RESTORE Citrus Tylactin RESTORE Powder Berry Tylactin BUILD 20	Tyros 1 Tyros 2	TYR Anamix Early Years TYR Anamix Next	TYR gel [™] TYR express [™] plus 15,20 TYR cooler [®] 15 *TYR sphere [®] 20
Older Children & Adults	Tyrex-2	*Tylactin Complete Tylactin RTD 15 Tylactin RESTORE Citrus Tylactin RESTORE Powder Berry Tylactin BUILD 20	Tyros 2	TYR Anamix Next	TYR express plus 15, 20 TYR cooler 15 *TYR sphere 20

^{*}Product contains GMP

Medical Therapy ¹

Nitisinone (NTBC)

Orfadin® <u>www.orfadin.com</u>
NITYRTM <u>www.cyclepharma.com</u>

- Starting dose: 1 mg/kg/d, increase to 2 mg/kg/d for those in acute severe liver failure
- Goal blood NTBC concentration- 30-70 μmol/L

Laboratory Monitoring ¹

Plasma succinylacetone A,D,G Serum AFP concentration A,E,G BUN/Creat H ALT/AST B,F Plasma Amino Acids A,D,G PT/PTT A,F Calcium H CBC B,F Blood NTBC concentration C,D,G Bicarbonate H Phosphorous H

- ^AAt initiation of treatment, then monthly for the first year of life
- $^{\rm B}\!$ At initiation of treatment, then every 3 months for the first year of life
- ^c Monthly for the first year of life
- $^{\text{\scriptsize D}}$ Every 3 months from age 1 year thru 5 years

- ^E Every 6 months from age 1 year thru 5 years
- F Annually after 1 year of age
- $^{\rm G}\,\mbox{Every}$ 6 months after age 5 years
- $^{\rm H}\,\mbox{At}$ initiation then annually

References

- 1. Chinsky JM, et al. Diagnosis and treatment of tyrosinemia type 1: a US and Canadian consensus group review and recommendations. Genetics in Medicine, Aug 2017.
- 2. Acosta PB. Nutrition Support Protocols: The Ross Metabolic Formula System. Abbot Laboratories, 2001